Remember Rember, Taurx Therapeutics Ltd Announces Clinical Trials
A major breakthrough inwards the handling of Alzheimer's illness was revealed past times scientists at the Alzheimer's Association International Conference on Alzheimer's Disease inwards 2008 (ICAD 2008).
The tiny, little, was bombarded past times visitors looking for information on the this novel wonder drug called - Rember. The Alzheimer's Community was thirsty for news. After all, TauRx were selected past times the Alzheimer's Association to acquaint their Phase 2 clinical trial findings.
And in addition to thus the silence. Nothing. Well to a greater extent than frequently than non hype until yesterday inwards Monte Carlo at CTAD - the fifth edition of Clinical Trials on Alzheimer’s Disease (CtaD) 2012.
Yesterday, TauRx Therapeutics Ltd announced the initiation of 2 global Phase 3 clinical trials inwards mild to moderate Alzheimer’s disease.
| Subscribe to the |
Influenza A virus subtype H5N1 quick cheque at ClinicalTrials.gov does demo 2 clinical trials equally scheduled to opened upward merely they are non nonetheless recruiting patients. No clinical trial locations are listed for either trial.
You tin move honour an an e-mail listed for contact on the pages describing the inclusion/exclusion criteria, etc., for the Phase 3 clinical trials.
Here are the 2 listings on ClinicalTrials.gov.
Safety in addition to Efficacy Study Evaluating TRx0237 inwards Subjects With Mild to Moderate Alzheimer's Disease. ClinicalTrials.gov Identifier: NCT01689246. Enrollment 833 patients.
Safety in addition to Efficacy Study Evaluating TRx0237 inwards Subjects With Mild Alzheimer's Disease. ClinicalTrials.gov Identifier: NCT01689233. Enrollment 500 patients.
You tin move honour all the available clinical trial information past times next the 2 links above. You tin move too read nigh - Rember - past times searching the ARR noesis base.
Here is the Company press release.
Announcing a novel era inwards Alzheimer’s
The fourth dimension for Tau is instantly equally Phase 3 clinical trials acquire nether way with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer’s
TauRx Therapeutics Ltd announced today the initiation of 2 global Phase 3 clinical trials inwards mild to moderate Alzheimer’s disease.
These landmark studies could furnish the get-go definitive information on a Tau-based approach to disease-modifying in addition to preventative handling of Alzheimer’s for at least the side past times side 5–7 years, said Professor Claude Wischik, Chairman of TauRx and Professor of Old Age Psychiatry at the University of Aberdeen, inwards a press conference at the fifth Clinical Trials Conference on Alzheimer’s Disease (CTAD) inwards Monte Carlo,
Monaco today.
The studies culminate 3 decades of inquiry past times Professor Wischik in addition to colleagues, including the master uncovering of the Tau poly peptide equally the primary constituentof the Tangle pathology of Alzheimer’s illness [‘Tau tangles’], the evolution of the get-go Tau Aggregation Inhibitor (TAI), in addition to results from an before Phase 2 clinical trial involving to a greater extent than than 300 patients that showed a 90% reduction inwards the charge per unit of measurement of
illness progression over 2 years.
“These Phase 3 studies are bringing us closer to finding an effective handling that can truly arrest the progression of the disease,” said Professor Wischik. “We are building on over xxx years of research, in addition to the encouraging results from our previous Phase 2 clinical trial inwards Alzheimer’s illness back upward an approach which targets the abnormal Tau aggregates inwards the brain.”
The studies, which select already starting enrolling inwards the U.S., aim to confirm the disease-modifying effects seen inwards the Phase 2 studies inwards mild to moderate patients over an 18-month timeframe. The get-go study volition involve 833 people with mild to moderate Alzheimer’s illness over 12 months.
The instant study volition include 500 people with mild Alzheimer’s illness over xviii months.
The study drug, ™, is a second-generation TAI that targets the Tau tangles and their precursors, dissolving them inwards guild to stop their harmful effects on memory.
LMTX™ too plant on the early on phase Tau aggregates (called ‘oligomers’) which are precursors to fully-formed tangles in addition to are thought to be particularly toxic.
“Clinicians devoted to Alzheimer’s illness select been waiting for a promising agent with disease-modifying properties,” said Professor Serge Gauthier of the McGill Centre for Studies inwards Aging, Quebec, Canada. “The basic scientific discipline information for this agent, particularly inwards the tauopathies, looks audio in addition to the involvement with investigators in addition to among families is high.” Professor Gauthier is a clinical investigator in addition to scientific
advisor for TauRx.
In a recent PharmaVoice article, William Thies, PhD, Chief Medical in addition to Scientific Officer of the Alzheimer’s Association, commented that researching Tau equally a therapeutic agent inwards Alzheimer’s is a solid path to follow, since Tau tangles are 1 of the hallmark lesions identified inwards the disease.
The tangles inwards the encephalon were first reported past times Dr. Alois Alzheimer inwards 1907, starting the century-long journeying to understand the pathology leading to their formation, their role inwards dementia, and,
ultimately, how to cease their spread through the brain.
Professor Lon Schneider, MD, of the Keck School of Medicine at the University of Southern California, a scientific advisor for TauRx, said: “Successfully targeting Tau may last an of import approach towards slowing in addition to ideally halting the neurodegeneration that is feature of Alzheimer’s illness or frontotemporal dementia. Clinicians request these Phase 3 studies to make clear evidence that such
an approach could atomic number 82 to improved patient outcomes.”
Countries inwards which the Phase 3 clinical trials volition last conducted include Australia, Belgium, Canada, Finland, France, Germany, Italy, Russia, Spain, Netherlands, Singapore, Malaysia, Taiwan, U.S., in addition to United Kingdom of Great Britain in addition to Northern Ireland Patients in addition to caregivers are invited to sign upward for study updates at www.AlzheimersStudies.com, equally the clinical trials are initiated inwards the countries selected.
About Alzheimer’s Disease in addition to Tau Tangles:
Alzheimer’s illness is 1 of the most of import wellness challenges worldwide, and the most-common type of dementia. According to the Geneva-based World Health Organization, global dementia cases are expected to double within xx years to an estimated 65.7 meg people [more than the entire population of French Republic currently at 63 meg people].
In real early, asymptomatic Alzheimer’s, pre-tangle Tau aggregates (oligomers) in addition to Tau poly peptide tangles are already acquaint inwards the same regions of the encephalon where neuronal degeneration in addition to loss of neuronal cells
eventually occur.
These changes get-go appear xx – 30 years before the illness becomes clinically evident. With time, Tau tangles spread from the entorhinal cortex (responsible for learning, memory, thinking in addition to planning) through the hippocampus to the neocortex (affecting the mightiness to communicate, recognize household unit of measurement in addition to loved ones in addition to to help for oneself), resulting inwards neuronal dysfunction in addition to worsening of clinical symptoms.
The spread is instantly thought to last due to a prion-like process whereby the oligomers deed equally ‘infectious particles’ which are able to propagate the abnormal aggregation of Tau poly peptide from 1 neurone to the next.
These oligomers recruit normal Tau to make nonetheless to a greater extent than infectious oligomers which spread
neuronal devastation throughout the brain.
About TauRx Therapeutics:
TauRx Therapeutics Ltd was established inwards Singapore inwards 2002 with the aim of developing novel treatments in addition to diagnostics for a hit of neurodegenerative diseases based on an exclusively novel approach which targets aggregates of abnormal fibres of Tau poly peptide that shape within nervus cells inwards the brain, giving rising to Tangles.
The TauRx squad select since discovered that LMTX™ could too select beneficial effects inwards several other neurodegenerative diseases associated with Tau pathology, as good equally other poly peptide aggregation disorders including Parkinson’s, Huntington’s,Frontotemporal Dementia [FTD-Pick’s Disease], Progressive Supranuclear Palsy and Cortico-Basal Degeneration. While TauRx corporate headquarters are inwards Singapore,
its primary inquiry facilities are inwards Aberdeen, Scotland.
- Alzheimer's Disease Statistics
- Test Your Memory for Alzheimer's (5 Best Tests)
- What is the Difference Between Alzheimer’s in addition to Dementia
- Dementia in addition to the Eight Types of Dementia
- What is Alzheimer's Disease?
- Why I Invented Alzheimer's World in addition to the Power of Positive Reinforcement
- Learning How to Communicate with Someone Suffering From Alzheimer's Disease
Original content Bob DeMarco, the